Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels

David M. Simpson, Anna Bettina Haidich, Giovanni Schifitto, Constantin T. Yiannoutsos, Anthony P. Geraci, Justin C. McArthur, David A. Katzenstein, H. Sacks, A. Khan, P. Gerits, J. Bartlett, J. Maenza, K. Carter, R. Becker, V. Rexrod, B. Cohen, C. Cooper, R. Murphy, J. Phair, J. R. BergerS. Ryan, A. Nath, R. Greenberg, S. Klenner, M. Ryan, R. Reichman, K. Kieburtz, M. Shoemaker, B. Navia, M. Hirsch, E. McCarthy, T. Flynn, B. Adornato, D. Slamowitz, S. Valle, J. Norris, M. Rubin, L. Ponticello, I. Zaprianova, C. Hall, C. Kapoor, C. Van der Horst, W. Robertson, E. Singer, E. Miller, S. A. Chafey, R. Mitsuyasu, R. McKendall, R. Pollard, H. Hollander, M. Jacobson, R. Price, D. McGuire, M. Freimer, J. Mendell, M. Tucker, M. Lederman, R. McVey, A. Davidson, C. Marra, D. Cummings, A. C. Collier, D. Clifford, K. Gray, M. Glicksman, W. Powderly, S. Hillman, E. Caten, B. Smith, S. Shriver, L. Millar, C. Rask

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Objective: To determine if there is an association between plasma HIV-1 RNA levels and severity of HIV-associated distal symmetrical polyneuropathy (DSP). Design: Substudy of AIDS Clinical Trials Group Protocol 291, a double-blind, placebo-controlled study of recombinant human nerve growth factor for the treatment of painful DSP. Methods: Two-hundred and thirty-six subjects had plasma HIV-1 RNA load assayed at baseline. Mean and maximum neuropathic pain was assessed once daily by the Gracely Pain Scale. Other measures included subjects' global pain assessment and quantitative sensory tests (QST). These values were correlated with baseline HIV-1 RNA levels. Results: Among 168 subjects with detectable plasma HIV-1 RNA, there was a significant correlation between plasma HIV-1 RNA and the severity of maximum and global pain, and toe cooling thresholds. Maximum and global pain assessment correlated with plasma HIV-1 RNA in individuals with detectable viral load (r, 0.162 and 0.194; P = 0.04 and 0.01, respectively). Conclusions: There is an association between plasma HIV-1 RNA levels and the severity of pain and QST results in HIV-associated DSP. Further studies are needed to determine if aggressive use of antiretroviral drugs, including the use of dideoxynucleosides, may be of benefit to prevent or improve peripheral neuropathy.

Original languageEnglish (US)
Pages (from-to)407-412
Number of pages6
JournalAIDS
Volume16
Issue number3
DOIs
StatePublished - Feb 15 2002

Fingerprint

HIV-1
HIV
RNA
Polyneuropathies
Pain Measurement
Pain
Dideoxynucleosides
Toes
Neuralgia
Peripheral Nervous System Diseases
Nerve Growth Factor
Clinical Protocols
Viral Load
Acquired Immunodeficiency Syndrome
Placebos
Clinical Trials
Pharmaceutical Preparations

Keywords

  • HIV
  • Neuropathic pain
  • Peripheral neuropathy
  • Plasma viral load

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Simpson, D. M., Haidich, A. B., Schifitto, G., Yiannoutsos, C. T., Geraci, A. P., McArthur, J. C., ... Rask, C. (2002). Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS, 16(3), 407-412. https://doi.org/10.1097/00002030-200202150-00012

Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. / Simpson, David M.; Haidich, Anna Bettina; Schifitto, Giovanni; Yiannoutsos, Constantin T.; Geraci, Anthony P.; McArthur, Justin C.; Katzenstein, David A.; Sacks, H.; Khan, A.; Gerits, P.; Bartlett, J.; Maenza, J.; Carter, K.; Becker, R.; Rexrod, V.; Cohen, B.; Cooper, C.; Murphy, R.; Phair, J.; Berger, J. R.; Ryan, S.; Nath, A.; Greenberg, R.; Klenner, S.; Ryan, M.; Reichman, R.; Kieburtz, K.; Shoemaker, M.; Navia, B.; Hirsch, M.; McCarthy, E.; Flynn, T.; Adornato, B.; Slamowitz, D.; Valle, S.; Norris, J.; Rubin, M.; Ponticello, L.; Zaprianova, I.; Hall, C.; Kapoor, C.; Van der Horst, C.; Robertson, W.; Singer, E.; Miller, E.; Chafey, S. A.; Mitsuyasu, R.; McKendall, R.; Pollard, R.; Hollander, H.; Jacobson, M.; Price, R.; McGuire, D.; Freimer, M.; Mendell, J.; Tucker, M.; Lederman, M.; McVey, R.; Davidson, A.; Marra, C.; Cummings, D.; Collier, A. C.; Clifford, D.; Gray, K.; Glicksman, M.; Powderly, W.; Hillman, S.; Caten, E.; Smith, B.; Shriver, S.; Millar, L.; Rask, C.

In: AIDS, Vol. 16, No. 3, 15.02.2002, p. 407-412.

Research output: Contribution to journalArticle

Simpson, DM, Haidich, AB, Schifitto, G, Yiannoutsos, CT, Geraci, AP, McArthur, JC, Katzenstein, DA, Sacks, H, Khan, A, Gerits, P, Bartlett, J, Maenza, J, Carter, K, Becker, R, Rexrod, V, Cohen, B, Cooper, C, Murphy, R, Phair, J, Berger, JR, Ryan, S, Nath, A, Greenberg, R, Klenner, S, Ryan, M, Reichman, R, Kieburtz, K, Shoemaker, M, Navia, B, Hirsch, M, McCarthy, E, Flynn, T, Adornato, B, Slamowitz, D, Valle, S, Norris, J, Rubin, M, Ponticello, L, Zaprianova, I, Hall, C, Kapoor, C, Van der Horst, C, Robertson, W, Singer, E, Miller, E, Chafey, SA, Mitsuyasu, R, McKendall, R, Pollard, R, Hollander, H, Jacobson, M, Price, R, McGuire, D, Freimer, M, Mendell, J, Tucker, M, Lederman, M, McVey, R, Davidson, A, Marra, C, Cummings, D, Collier, AC, Clifford, D, Gray, K, Glicksman, M, Powderly, W, Hillman, S, Caten, E, Smith, B, Shriver, S, Millar, L & Rask, C 2002, 'Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels', AIDS, vol. 16, no. 3, pp. 407-412. https://doi.org/10.1097/00002030-200202150-00012
Simpson DM, Haidich AB, Schifitto G, Yiannoutsos CT, Geraci AP, McArthur JC et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS. 2002 Feb 15;16(3):407-412. https://doi.org/10.1097/00002030-200202150-00012
Simpson, David M. ; Haidich, Anna Bettina ; Schifitto, Giovanni ; Yiannoutsos, Constantin T. ; Geraci, Anthony P. ; McArthur, Justin C. ; Katzenstein, David A. ; Sacks, H. ; Khan, A. ; Gerits, P. ; Bartlett, J. ; Maenza, J. ; Carter, K. ; Becker, R. ; Rexrod, V. ; Cohen, B. ; Cooper, C. ; Murphy, R. ; Phair, J. ; Berger, J. R. ; Ryan, S. ; Nath, A. ; Greenberg, R. ; Klenner, S. ; Ryan, M. ; Reichman, R. ; Kieburtz, K. ; Shoemaker, M. ; Navia, B. ; Hirsch, M. ; McCarthy, E. ; Flynn, T. ; Adornato, B. ; Slamowitz, D. ; Valle, S. ; Norris, J. ; Rubin, M. ; Ponticello, L. ; Zaprianova, I. ; Hall, C. ; Kapoor, C. ; Van der Horst, C. ; Robertson, W. ; Singer, E. ; Miller, E. ; Chafey, S. A. ; Mitsuyasu, R. ; McKendall, R. ; Pollard, R. ; Hollander, H. ; Jacobson, M. ; Price, R. ; McGuire, D. ; Freimer, M. ; Mendell, J. ; Tucker, M. ; Lederman, M. ; McVey, R. ; Davidson, A. ; Marra, C. ; Cummings, D. ; Collier, A. C. ; Clifford, D. ; Gray, K. ; Glicksman, M. ; Powderly, W. ; Hillman, S. ; Caten, E. ; Smith, B. ; Shriver, S. ; Millar, L. ; Rask, C. / Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. In: AIDS. 2002 ; Vol. 16, No. 3. pp. 407-412.
@article{0015ed688c20462eb51e9a7f918896b6,
title = "Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels",
abstract = "Objective: To determine if there is an association between plasma HIV-1 RNA levels and severity of HIV-associated distal symmetrical polyneuropathy (DSP). Design: Substudy of AIDS Clinical Trials Group Protocol 291, a double-blind, placebo-controlled study of recombinant human nerve growth factor for the treatment of painful DSP. Methods: Two-hundred and thirty-six subjects had plasma HIV-1 RNA load assayed at baseline. Mean and maximum neuropathic pain was assessed once daily by the Gracely Pain Scale. Other measures included subjects' global pain assessment and quantitative sensory tests (QST). These values were correlated with baseline HIV-1 RNA levels. Results: Among 168 subjects with detectable plasma HIV-1 RNA, there was a significant correlation between plasma HIV-1 RNA and the severity of maximum and global pain, and toe cooling thresholds. Maximum and global pain assessment correlated with plasma HIV-1 RNA in individuals with detectable viral load (r, 0.162 and 0.194; P = 0.04 and 0.01, respectively). Conclusions: There is an association between plasma HIV-1 RNA levels and the severity of pain and QST results in HIV-associated DSP. Further studies are needed to determine if aggressive use of antiretroviral drugs, including the use of dideoxynucleosides, may be of benefit to prevent or improve peripheral neuropathy.",
keywords = "HIV, Neuropathic pain, Peripheral neuropathy, Plasma viral load",
author = "Simpson, {David M.} and Haidich, {Anna Bettina} and Giovanni Schifitto and Yiannoutsos, {Constantin T.} and Geraci, {Anthony P.} and McArthur, {Justin C.} and Katzenstein, {David A.} and H. Sacks and A. Khan and P. Gerits and J. Bartlett and J. Maenza and K. Carter and R. Becker and V. Rexrod and B. Cohen and C. Cooper and R. Murphy and J. Phair and Berger, {J. R.} and S. Ryan and A. Nath and R. Greenberg and S. Klenner and M. Ryan and R. Reichman and K. Kieburtz and M. Shoemaker and B. Navia and M. Hirsch and E. McCarthy and T. Flynn and B. Adornato and D. Slamowitz and S. Valle and J. Norris and M. Rubin and L. Ponticello and I. Zaprianova and C. Hall and C. Kapoor and {Van der Horst}, C. and W. Robertson and E. Singer and E. Miller and Chafey, {S. A.} and R. Mitsuyasu and R. McKendall and R. Pollard and H. Hollander and M. Jacobson and R. Price and D. McGuire and M. Freimer and J. Mendell and M. Tucker and M. Lederman and R. McVey and A. Davidson and C. Marra and D. Cummings and Collier, {A. C.} and D. Clifford and K. Gray and M. Glicksman and W. Powderly and S. Hillman and E. Caten and B. Smith and S. Shriver and L. Millar and C. Rask",
year = "2002",
month = "2",
day = "15",
doi = "10.1097/00002030-200202150-00012",
language = "English (US)",
volume = "16",
pages = "407--412",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels

AU - Simpson, David M.

AU - Haidich, Anna Bettina

AU - Schifitto, Giovanni

AU - Yiannoutsos, Constantin T.

AU - Geraci, Anthony P.

AU - McArthur, Justin C.

AU - Katzenstein, David A.

AU - Sacks, H.

AU - Khan, A.

AU - Gerits, P.

AU - Bartlett, J.

AU - Maenza, J.

AU - Carter, K.

AU - Becker, R.

AU - Rexrod, V.

AU - Cohen, B.

AU - Cooper, C.

AU - Murphy, R.

AU - Phair, J.

AU - Berger, J. R.

AU - Ryan, S.

AU - Nath, A.

AU - Greenberg, R.

AU - Klenner, S.

AU - Ryan, M.

AU - Reichman, R.

AU - Kieburtz, K.

AU - Shoemaker, M.

AU - Navia, B.

AU - Hirsch, M.

AU - McCarthy, E.

AU - Flynn, T.

AU - Adornato, B.

AU - Slamowitz, D.

AU - Valle, S.

AU - Norris, J.

AU - Rubin, M.

AU - Ponticello, L.

AU - Zaprianova, I.

AU - Hall, C.

AU - Kapoor, C.

AU - Van der Horst, C.

AU - Robertson, W.

AU - Singer, E.

AU - Miller, E.

AU - Chafey, S. A.

AU - Mitsuyasu, R.

AU - McKendall, R.

AU - Pollard, R.

AU - Hollander, H.

AU - Jacobson, M.

AU - Price, R.

AU - McGuire, D.

AU - Freimer, M.

AU - Mendell, J.

AU - Tucker, M.

AU - Lederman, M.

AU - McVey, R.

AU - Davidson, A.

AU - Marra, C.

AU - Cummings, D.

AU - Collier, A. C.

AU - Clifford, D.

AU - Gray, K.

AU - Glicksman, M.

AU - Powderly, W.

AU - Hillman, S.

AU - Caten, E.

AU - Smith, B.

AU - Shriver, S.

AU - Millar, L.

AU - Rask, C.

PY - 2002/2/15

Y1 - 2002/2/15

N2 - Objective: To determine if there is an association between plasma HIV-1 RNA levels and severity of HIV-associated distal symmetrical polyneuropathy (DSP). Design: Substudy of AIDS Clinical Trials Group Protocol 291, a double-blind, placebo-controlled study of recombinant human nerve growth factor for the treatment of painful DSP. Methods: Two-hundred and thirty-six subjects had plasma HIV-1 RNA load assayed at baseline. Mean and maximum neuropathic pain was assessed once daily by the Gracely Pain Scale. Other measures included subjects' global pain assessment and quantitative sensory tests (QST). These values were correlated with baseline HIV-1 RNA levels. Results: Among 168 subjects with detectable plasma HIV-1 RNA, there was a significant correlation between plasma HIV-1 RNA and the severity of maximum and global pain, and toe cooling thresholds. Maximum and global pain assessment correlated with plasma HIV-1 RNA in individuals with detectable viral load (r, 0.162 and 0.194; P = 0.04 and 0.01, respectively). Conclusions: There is an association between plasma HIV-1 RNA levels and the severity of pain and QST results in HIV-associated DSP. Further studies are needed to determine if aggressive use of antiretroviral drugs, including the use of dideoxynucleosides, may be of benefit to prevent or improve peripheral neuropathy.

AB - Objective: To determine if there is an association between plasma HIV-1 RNA levels and severity of HIV-associated distal symmetrical polyneuropathy (DSP). Design: Substudy of AIDS Clinical Trials Group Protocol 291, a double-blind, placebo-controlled study of recombinant human nerve growth factor for the treatment of painful DSP. Methods: Two-hundred and thirty-six subjects had plasma HIV-1 RNA load assayed at baseline. Mean and maximum neuropathic pain was assessed once daily by the Gracely Pain Scale. Other measures included subjects' global pain assessment and quantitative sensory tests (QST). These values were correlated with baseline HIV-1 RNA levels. Results: Among 168 subjects with detectable plasma HIV-1 RNA, there was a significant correlation between plasma HIV-1 RNA and the severity of maximum and global pain, and toe cooling thresholds. Maximum and global pain assessment correlated with plasma HIV-1 RNA in individuals with detectable viral load (r, 0.162 and 0.194; P = 0.04 and 0.01, respectively). Conclusions: There is an association between plasma HIV-1 RNA levels and the severity of pain and QST results in HIV-associated DSP. Further studies are needed to determine if aggressive use of antiretroviral drugs, including the use of dideoxynucleosides, may be of benefit to prevent or improve peripheral neuropathy.

KW - HIV

KW - Neuropathic pain

KW - Peripheral neuropathy

KW - Plasma viral load

UR - http://www.scopus.com/inward/record.url?scp=0037083761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037083761&partnerID=8YFLogxK

U2 - 10.1097/00002030-200202150-00012

DO - 10.1097/00002030-200202150-00012

M3 - Article

C2 - 11834952

AN - SCOPUS:0037083761

VL - 16

SP - 407

EP - 412

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 3

ER -